Hong Kan

Previously unrecognized risk factors for severe hypoglycaemia requiring emergency medical care in insulin‐treated type 2 diabetes: Results from a real‐world nested case‐control study

B. Frier, R. Wade, M. Gorritz, 2022, Diabetes, obesity & metabolism.

General versus central adiposity as risk factors for cardiovascular-related outcomes in a high-risk population with type 2 diabetes: a post hoc analysis of the REWIND trial

P. Pais, H. Gerstein, J. Basile, 2023, Cardiovascular Diabetology.

Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison

C. L. le Roux, M. Bunck, L. García‐Pérez, 2023, Diabetes, obesity & metabolism.

Real-world primary nonadherence to antiobesity medications.

J. Bae, E. Buysman, N. Gronroos, 2023, Journal of managed care & specialty pharmacy.

Weight management treatment modalities in patients with overweight or obesity: A retrospective cohort study of administrative claims data

J. Bae, E. Buysman, N. Gronroos, 2023, Obesity Pillars.

Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT‐1 post hoc analysis

E. R. Hankosky, Hong Kan, Fangyu Wang, 2023, Diabetes, obesity & metabolism.

Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT‐1 trial

Hong Wang, E. R. Hankosky, Hong Kan, 2023, Diabetes, obesity & metabolism.

Clinical, economic, and health‐related quality of life outcomes in patients with overweight or obesity in the United States: 2016–2018

S. Shinde, Hong Kan, J. Poon, 2023, Obesity science & practice.